Optical electrophysiology of human primary neurons: role of KCC2 in hyperexcitability induced by HIV-1, Tat, and gp120 and morphine exposure
人类原代神经元的光学电生理学:KCC2 在 HIV-1、Tat、gp120 和吗啡暴露诱导的过度兴奋中的作用
基本信息
- 批准号:9754573
- 负责人:
- 金额:$ 2.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-10 至 2020-01-09
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAIDS dementiaAcuteAddressAffectAminobutyric AcidsAnimal ModelAstrocytesBrainBrain-Derived Neurotrophic FactorCCR5 geneCXCR4 ReceptorsCalciumCellsChloride IonChronicComorbidityDataDiseaseDrug usageElectrophysiology (science)EnhancersEnvironmentEquilibriumExcitatory NeurotoxinsExposure toFunctional disorderGlutamatesHIVHIV Envelope Protein gp120HIV InfectionsHIV-1HIV-associated neurocognitive disorderHumanImageIn VitroIndividualInfectionInflammation MediatorsInflammatoryInterventionLeadLightMaintenanceMeasuresMediatingMediator of activation proteinMicrogliaModelingMorphineN-Methyl-D-Aspartate ReceptorsNeuronal DysfunctionNeuronsOpioidOpioid ReceptorOpticsOutcomePathologyPharmacologyPhysiologicalPlayPrevalencePropertyProteinsProtocols documentationReceptor ActivationReceptor Protein-Tyrosine KinasesResearchRoleSignal PathwaySignal TransductionStructureSymptomsSynapsesSystemT-LymphocyteTechniquesTestingWithdrawalWorkantiretroviral therapyastrocyte progenitorcalcium indicatorcell typechemokine receptorchloride-cotransporter potassiumexposed human populationfetalgamma-Aminobutyric Acidgamma-Chemokineshuman modelinhibitor/antagonistinnovationmacrophagemu opioid receptorsnerve stem cellnervous system disorderneuronal excitabilityneurotoxicnew therapeutic targetnovelopioid useopioid use disorderoptogeneticsreceptorrecruitreduce symptomsrelating to nervous systemresponsetoolvoltage
项目摘要
PROJECT SUMMARY
The introduction of combined antiretroviral therapy has decreased the prevalence of HIV-associated dementia,
but prevalence of milder HIV-associated neurocognitive disorders (HAND) has increased. The CNS is highly
vulnerable to insult from HIV-1 via release of neurotoxic HIV proteins, inflammatory factors, and excitotoxins by
infected astrocytes and microglia. Opiate use is often comorbid with HIV-1 infection and there is evidence for
enhanced HAND symptomology in users, likely due to convergent cell signaling pathways resulting in increased
neuronal dysfunction. Despite intense research the interactions between HIV-1 and opiates that lead to neuronal
damage remain elusive, and most of this work is conducted in animal models. Since HIV-1 is a human-specific
disease, it is paramount to validate and expand upon research findings in nonhuman models using human
models. To this end, we have differentiated human neural progenitors to develop two primary human CNS culture
models: i) a dissociated system containing glutamatergic and GABAergic neurons; and ii) a 3-dimensional brain
aggregate (BrAgg) model that contains all major CNS cell types. Using non-invasive electrophysiological
techniques including genetically encoded voltage and Ca2+ indicators (GEVI/GECI), and optogenetics we will
examine the effects of infectious HIV-1, Tat, and gp120 ± morphine on primary human neuron function. By
studying HIV-1 ± morphine effects on neuronal excitability we have uncovered a novel therapeutic target. K-Cl
cotransporter 2 (KCC2) maintains low neuronal [Cl-]i necessary for -aminobutyric acid type A receptor
(GABAAR)-mediated inhibition. Loss of KCC2 activity resulting in loss of GABAAR hyperpolarization, and even
GABA-induced depolarization, has been implicated in a variety of neurological disorders. This project tests the
hypothesis that HIV-1 and morphine-induced signaling converge to reduce neuronal KCC2 activity leading to
electrophysiological and synaptic excitatory-inhibitory imbalance in primary human neurons. Our data have
demonstrated significant loss of KCC2 and subsequent shift from hyper- to depolarization in response to GABA
in HIV-1, Tat, and gp120 ± morphine-exposed human neurons. Pharmacological intervention to raise KCC2
levels has reversed these effects. Aim 1 will utilize GEVI and GECI to determine functional responses to
infectious HIV-1, Tat, and gp120 (R5-, X4-, and dual-tropic) exposure on dissociated human neurons and
examine modulation of KCC2 and relevant upstream regulators (e.g. NMDAR, CCR5, CXCR4, opioid receptors)
to rescue noted deficits. Aim 2 will utilize stable BrAgg which contain all major CNS cell types and can be actively
infected by HIV-1. Tools and measures described in Aim 1 will be used to examine neuronal function in a chronic,
HIV-1-infected environment and elucidate differences between chronic, acute, and withdrawal morphine
exposure paradigms. These studies use innovative models and techniques to determine effects of live HIV-1,
Tat, and gp120 ± morphine on primary human neuron function and identify novel points of HIV-1 and morphine
signaling convergence and targets for intervention to alleviate the symptoms of HAND ± comorbid opiate use.
项目摘要
采用联合抗逆转录病毒疗法降低了艾滋病毒相关痴呆症的发病率,
但较轻的艾滋病相关神经认知障碍(HAND)的患病率有所增加。CNS高度
通过释放神经毒性HIV蛋白、炎症因子和兴奋性毒素,容易受到HIV-1的伤害,
感染的星形胶质细胞和小胶质细胞阿片类药物的使用通常与HIV-1感染共病,有证据表明,
使用者中增强的手神经学,可能是由于会聚细胞信号传导途径导致增加的
神经元功能障碍尽管进行了大量的研究,但HIV-1和阿片类药物之间的相互作用导致神经元
损伤仍然是难以捉摸的,并且大多数这项工作是在动物模型中进行的。由于HIV-1是人类特有的
疾病,最重要的是验证和扩大在非人类模型中的研究结果,使用人类
模型为此,我们分化了人神经祖细胞,以开发两种原代人CNS培养物
模型:i)含有谷氨酸能和GABA能神经元的分离系统;和ii)三维脑
聚集体(BrAgg)模型,其包含所有主要CNS细胞类型。使用非侵入性电生理学
包括遗传编码电压和Ca 2+指标(GEVI/GECI)和光遗传学技术,我们将
检测感染性HIV-1、达特和gp 120 ±吗啡对原代人类神经元功能的影响。通过
通过研究HIV-1 ±吗啡对神经元兴奋性的影响,我们发现了一个新的治疗靶点。氯化钾
协同转运蛋白2(KCC 2)维持低的神经元[Cl-]i,这是α-氨基丁酸A型受体所必需的
(GABAAR)介导的抑制。KCC 2活性丧失导致GABAAR超极化丧失,甚至
GABA诱导的去极化与多种神经系统疾病有关。该项目测试了
假设HIV-1和吗啡诱导的信号传导会聚集以降低神经元KCC 2活性,从而导致
电生理和突触兴奋-抑制不平衡的原代人类神经元。我们的数据
证明了KCC 2的显著损失和随后响应GABA从超极化到去极化的转变
在暴露于HIV-1、达特和gp 120 ±吗啡的人类神经元中。药物干预提高KCC 2
水平逆转了这些影响。目标1将利用GEVI和GECI来确定功能反应,
感染性HIV-1、达特和gp 120(R5-、X4-和双嗜性)暴露于分离的人神经元,
检查KCC 2和相关上游调节因子(如NMDAR、CCR 5、CXCR 4、阿片受体)的调节
以挽救明显的赤字。目的2将利用稳定的BrAgg,其含有所有主要的CNS细胞类型,并且可以被主动地
感染HIV-1。目标1中描述的工具和测量将用于检查慢性,
HIV-1感染的环境和阐明慢性,急性和戒断吗啡之间的差异
暴露范例。这些研究使用创新的模型和技术来确定活HIV-1的影响,
达特和gp 120 ±吗啡对原代人神经元功能的影响及HIV-1和吗啡的新作用点
信号收敛和干预的目标,以减轻手±共病阿片类药物使用的症状。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aaron Joseph Barbour其他文献
Aaron Joseph Barbour的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aaron Joseph Barbour', 18)}}的其他基金
Optical electrophysiology of human primary neurons: role of KCC2 in hyperexcitability induced by HIV-1, Tat, and gp120 and morphine exposure
人类原代神经元的光学电生理学:KCC2 在 HIV-1、Tat、gp120 和吗啡暴露诱导的过度兴奋中的作用
- 批准号:
9623656 - 财政年份:2018
- 资助金额:
$ 2.3万 - 项目类别:
相似海外基金
Green tea derived EGCG opposes AIDS dementia-like neuronal damage
绿茶提取的 EGCG 可以对抗艾滋病痴呆样神经元损伤
- 批准号:
7338235 - 财政年份:2007
- 资助金额:
$ 2.3万 - 项目类别:
Green tea derived EGCG opposes AIDS dementia-like neuronal damage
绿茶提取的 EGCG 可以对抗艾滋病痴呆样神经元损伤
- 批准号:
7460708 - 财政年份:2007
- 资助金额:
$ 2.3万 - 项目类别:
MT COBRE: MOLEC MODULATION OF GLUTAMATE TRANSPORTER EXPRESSION: AIDS DEMENTIA
MT COBRE:谷氨酸转运蛋白表达的分子调节:艾滋病痴呆
- 批准号:
7381173 - 财政年份:2006
- 资助金额:
$ 2.3万 - 项目类别:
SCAN ELECTRON MICROSCOPE: ROLE OF MICROGLIA IN INFECTION OF BRAIN, AIDS DEMENTIA
扫描电子显微镜:小胶质细胞在大脑感染、艾滋病痴呆中的作用
- 批准号:
7335212 - 财政年份:2006
- 资助金额:
$ 2.3万 - 项目类别:
HIV Sequence Evolution in AIDS Dementia Pathogenesis
艾滋病痴呆发病机制中的HIV序列进化
- 批准号:
7017818 - 财政年份:2005
- 资助金额:
$ 2.3万 - 项目类别:
HIV Sequence Evolution in AIDS Dementia Pathogenesis
艾滋病痴呆发病机制中的HIV序列进化
- 批准号:
7570712 - 财政年份:2005
- 资助金额:
$ 2.3万 - 项目类别:
HIV Sequence Evolution in AIDS Dementia Pathogenesis
艾滋病痴呆发病机制中的HIV序列进化
- 批准号:
7174625 - 财政年份:2005
- 资助金额:
$ 2.3万 - 项目类别:
HIV Sequence Evolution in AIDS Dementia Pathogenesis
艾滋病痴呆发病机制中的HIV序列进化
- 批准号:
7340483 - 财政年份:2005
- 资助金额:
$ 2.3万 - 项目类别:
HIV Sequence Evolution in AIDS Dementia Pathogenesis
艾滋病痴呆发病机制中的HIV序列进化
- 批准号:
6895006 - 财政年份:2005
- 资助金额:
$ 2.3万 - 项目类别:
Tat Interaction with LRP and Its Role in AIDS Dementia
Tat 与 LRP 的相互作用及其在艾滋病痴呆中的作用
- 批准号:
6748504 - 财政年份:2002
- 资助金额:
$ 2.3万 - 项目类别: